Prospective cohort reveals immunotherapy improves progression-free survival in gastric cancer, highlighting gut microbiota's role in overcoming therapeutic resistance.
Key Points
The study aims to explore the role of Eubacterium rectale and its metabolite butyrate in gastric cancer treatment and immunotherapy efficacy.
Analyzed a prospective gastric cancer cohort for Eubacterium rectale association with immunotherapy outcomes.
Conducted in vitro and in vivo experiments to assess tumor growth, apoptosis, and immune cell infiltration.
Performed targeted metabolomics on gut, serum, and tumor samples to measure short-chain fatty acid distribution.
Eubacterium rectale and butyrate significantly inhibited tumor growth and promoted apoptosis.
Treatment led to reduced PD-L1 expression and increased CD8+ T-cell infiltration in mouse models.
Observations suggest that gut microbiota enhances progression-free survival and overcomes immunotherapy resistance.